Related Experiment Video
Updated: Dec 18, 2025

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
Potential benefit of combination antifungal therapy in Aspergillus endocarditis
Kate Lennard1, Aiveen Bannan2, Peter Grant3
1Infectious Diseases, Prince of Wales Hospital and Community Health Services, Randwick, New South Wales, Australia.
Abstract:
Aspergillus endocarditis (AE) is a rare condition with a mortality rate greater than 60%. While it is generally accepted that both antifungal therapy and surgery are necessary for survival, the optimal antifungal regimen is unclear. A 62-year-old man was diagnosed with AE of a prosthetic aortic valve, complicated by cerebral emboli. He underwent debridement of the aortic valve abscess and valve replacement, and was managed with a combination of liposomal amphotericin B and voriconazole for 7 weeks followed by long-term suppressive azole therapy. He remained well at follow-up 18 months later. Data from a review of case reports published between 1950 and 2010 revealed greater survival rates in patients managed with two or more antifungals as opposed to single agent therapy. We provide an updated literature review with similar findings, suggesting that dual agent antifungal therapy should be considered in patients with AE.
Insights
Aspergillus endocarditis (AE) is a serious fungal infection. Dual antifungal therapy, combined with surgery, may improve survival rates in patients with AE.
Area of Science:
- Infectious Diseases
- Cardiology
- Mycology
Background:
- Aspergillus endocarditis (AE) presents a significant challenge with high mortality rates exceeding 60%.
- Optimal antifungal treatment strategies for AE remain incompletely defined.
- Surgical intervention is typically considered essential for AE management.
Observation:
- A case of prosthetic aortic valve AE complicated by cerebral emboli was successfully treated.
- The patient received combined liposomal amphotericin B and voriconazole for 7 weeks, followed by suppressive azole therapy.
- The patient demonstrated positive outcomes at 18-month follow-up.
Findings:
- A literature review of AE cases (1950-2010) indicated higher survival with multiple antifungal agents versus monotherapy.
- An updated literature review corroborated these findings, supporting dual antifungal therapy for AE.
- Combination antifungal therapy demonstrated efficacy in the presented case.
Implications:
- Dual antifungal therapy should be strongly considered for patients diagnosed with Aspergillus endocarditis.
- Aggressive combined medical and surgical management may improve outcomes in AE.
- Further research into optimal antifungal regimens for AE is warranted.
More Related Videos
Related Concept Videos
Endocarditis III: Medical Management
Endocarditis IV: Nursing Management
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Endocarditis I: Introduction
Endocarditis II: Clinical Features of Infective Endocarditis
Myocarditis III: Medical Management

